Clinical characteristics, treatment outcomes, and survival of patients with primary bone diffuse large b-cell lymphoma: a single-center retrospective analysis
Journal of Current Hematology & Oncology Research · 13.11.2026 · 4 (4) · 152-158
DOI: 10.51271/jchor-0100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Current Hematology & Oncology Research, online erschienen am 13.11.2026. Verfasst von Asu Fergün Yılmaz und 11 weiteren Autor:innen.
Abstract (Originalsprache)
Aims
Primary bone diffuse large B-cell lymphoma (PB-DLBCL) is a rare extranodal lymphoma with generally favorable outcomes following anthracycline-based immunochemotherapy. However, the prognostic impact of disease distribution remains poorly defined, and only a limited number of studies have reported treatment outcomes separately for patients with unifocal (UF) and multifocal (MF) disease. This study aimed to evaluate the clinical characteristics, treatment outcomes, survival, and safety of PB-DLBCL, with particular emphasis on differences between UF and MF disease.
Methods
This retrospective single-center study included 13 consecutive adult patients with histologically confirmed PB-DLBCL diagnosed between 2010 and 2025. Patients were classified as UF (n=9) or MF (n=4) according to the number of involved bone sites. Clinical characteristics, treatment response, survival outcomes, and treatment-related adverse events were analyzed.
Results
The median age was 59 years (range, 18–78), and localized bone pain was the most common presenting symptom (92.3%). Patients with MF disease tended to present with more adverse clinical features, including bulky lesions, elevated lactate dehydrogenase levels, larger lesions, and poorer performance status. Complete and partial responses were achieved in 9 (69.2%) and 1 (7.7%) patient, respectively, yielding an overall response rate of 76.9%. The overall response rate was 100% in the UF group compared with 25% in the MF group (p=0.014). The median overall survival was 88.15 months, with a 2-year overall survival rate of 91.7%; the corresponding 2-year overall survival rates were 100% and 66.7% in the UF and MF groups, respectively. Hematologic toxicities were the most common adverse events, while grade 3–4 toxicities were infrequent and treatment was generally well tolerated.
Conclusion
Anthracycline-based immunochemotherapy provides excellent outcomes for most patients with PB-DLBCL. However, MF disease is associated with substantially inferior treatment response and survival compared with UF disease. Despite the limited sample size, our findings add to the scarce literature evaluating UF and MF disease separately and further support disease distribution as an important prognostic factor in PB-DLBCL. Future multicenter studies are warranted to validate these findings and optimize treatment strategies for patients with MF disease.
Zitieren
APA
Yılmaz, A. F., Mengüç, M. U., Ercan, T., Bayar, A., Guren, C. U., Özince, R. B. D., Özerol, S., Temiz, F., Sakçı, E., Arıkan, F., Toptaş, T., & Atagündüz, I. (2026). Clinical characteristics, treatment outcomes, and survival of patients with primary bone diffuse large b-cell lymphoma: a single-center retrospective analysis. Journal of Current Hematology & Oncology Research, 4(4), 152-158. https://doi.org/10.51271/jchor-0100
Vancouver
Yılmaz AF, Mengüç MU, Ercan T, Bayar A, Guren CU, Özince RBD, et al. Clinical characteristics, treatment outcomes, and survival of patients with primary bone diffuse large b-cell lymphoma: a single-center retrospective analysis. Journal of Current Hematology & Oncology Research. 2026;4(4):152-158. doi:10.51271/jchor-0100
BibTeX
@article{Ylmaz2026,
author = {Yılmaz, Asu Fergün and Mengüç, Meral Uluköylü and Ercan, Tarık and Bayar, Arda and Guren, Ceren Uzunoğlu and Özince, Rana Berru Durmuş and Özerol, Semih and Temiz, Fatma and Sakçı, Elif and Arıkan, Fatma and Toptaş, Tayfur and Atagündüz, Işık},
title = {Clinical characteristics, treatment outcomes, and survival of patients with primary bone diffuse large b-cell lymphoma: a single-center retrospective analysis},
journal = {Journal of Current Hematology & Oncology Research},
year = {2026},
volume = {4},
number = {4},
pages = {152--158},
doi = {10.51271/jchor-0100}
}
EUVIMED